1Malfertheiner P, Mégraud F, O Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther,2002,16:167-180.
2Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds.Helicobacter pylori: Physiology and Genetics. Washington DC:ASM Press,2001. 511-530.
3Mégraud F. Helicobacter pylori and macrolides. In: Schonfeld W, Kirst HA, eds. Macrolide antibiotics. Berlin: Birkhauser,2002. 243-260.
4Gisbert JP, Calvet X, Bujanda L, et al. Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures.Helicobacter, 2003,8: 90-94.
5Masconi G, Parente F, Russo A, et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol, 2001,96: 359-366.
6Baena JM, Lopez C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol, 2002,14: 291-296.
7Amieva MR, Salama NR, Tompkins LS, et al. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol, 2002,4 : 677-690.
8Matysiak-Budnik T, Heyman M, Candalh C, et al. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier. J Antimicrob Chemother, 2002,50: 865-872.
9Rabelo-Goncalves EM, Nishimura NF, Zeitune JM. Acute inflammatory response in the stomach of BALB/c mice chal lenged with coccoidal Helicobacter pylori. Mem Inst Oswaldo Cruz,2002,97:1201-1206.
10Broutet N, Tchamgoué S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy. Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther, 2003,17:99-109.
